Naloxone Market: Region Wise Analysis of Top Players in Market by its Types and Application 2018-2026 Mylan N.V., Novartis AG, Indivior Plc., ADAPT Pharma Inc., Amphastar Pharmaceuticals Inc., INSYS Therapeutics Inc.

Naloxone is an opioid antagonist used to counter the effects of opioid overdose, such as morphine and heroine. Naloxone is indicated for use in opioid overdose to counteract life-threatening depression of the central nervous system and respiratory system, allowing an overdose victim to breathe normally. Naloxone is non-scheduled prescription medication, which in most cases, is administrated by emergency response personnel or minimally trained personnel, and is thus ideal for treating overdose in people who are prescribed opioid pain medication. Naloxone can be administrated through parenteral route, by injecting in the muscle or vein.

Market Dynamics

Increasing launches and approval of new naloxone products in the market is expected to drive the global naloxone market growth over the forecast period. In October, 2016 Health Canada approved Narcan Nasal Spray 4 mg for non-prescription, community use in Canada

Download PDF Brochure of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-pdf/1804

Rising prevalence of opioid overdose in key regions such as North America, and Europe is expected to drive demand for naloxone products and drive the naloxone market growth in the near future. For instance, according to the data published by European Monitoring Center for Drugs and Drug Addiction (EMCDDA), in 2016, around 150,943 high-risk opioid users were reported in Germany and around 330,445 were reported in the U.K.

Furthermore, initiatives by various government and private organizations to increase access of naloxone product among the population is also expected to drive market growth. For instance, in 2015, Kaleo, Inc. partnered with the Clinton Foundation and provided bulk discounts on its EVZIO to various college universities and public safety organizations.

Frequent Launches And Approvals Of Novel Naloxone Products Is Expected To Fuel The Global Naloxone Market Growth

Increasing launches and approval of novel naloxone products by various regulatory bodies is expected to be a major factor aiding in growth of the market over the forecast period. For instance, in January 2017, the U.S. Food and Drug Administration (FDA) approved Adapt Pharma Inc.’s NARCAN Nasal Spray 2 mg formulation for emergency treatment of known or suspected opioid overdose. In 2016, Mylan N.V. launched its naloxone hydrochloride injection USP, 0.4 mg/mL packaged in 1 mL single-dose vials. It is therapeutically equivalent to the naloxone hydrochloride injection 0.4 mg/mL, of Hospira Inc. In September 2017, Mundipharma International Limited received approval from European Medicines Agency (EMA) for its product (intranasal naloxone 1.8 mg) to use in emergency reversal of opioid overdose. The global naloxone market size was valued at US$ 310.2 Mn in 2017, and is expected to witness a CAGR of 11.4% over the forecast period (2018 – 2026).

Increasing Drug Abuse In Key Regions Is Expected To Increase Demand For Its Treatment Drugs

Increasing cases of opioid overdose is expected to increase demand for naloxone products during emergency treatments which in turn will positively drive the global naloxone market growth. For instance, according to the data published by the U.S. Department of Health and Human Services (HHS) in 2016, around 11.5 million people misuse prescription drugs and around 948,000 people use heroin. According to the data published by National Institute on Drug Abuse, 2018, in the U.S., everyday over 115 people die due to opioid overdosing. According to same source, in the U.S. opioid overdose increased by 30% from July 2016 through September 2017 in 52 areas in 45 states.

Request For Customization Of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-customization/1804

Competitive Landscape

Mylan N.V., Novartis AG, Indivior Plc., ADAPT Pharma, Inc., Amphastar Pharmaceuticals, Inc., INSYS Therapeutics, Inc., Mundipharma International Limited, Kaleo, Inc., and Kern Pharma, S.L.

Detailed Segmentation:

Global Naloxone Market, By Strength:
0.4 mg/ml
1mg/ml
0.4mg/0.4ml
4mg/0.1ml and Others

Global Naloxone Market, By Drug Type:
Intranasal
Intramuscular/Subcutaneous
Intravenous

Global Naloxone Market, By Distribution Channel:
Hospitals
Clinics
Retail Pharmacies
Online Pharmacies
Others

Favorable Reimbursement Scenarios For Naloxone Products Is Also Expected To Aid In Market Growth

Reimbursement scenario for drugs play a major role in adoption of high cost products in developed regions such as North America and Europe. Therefore, favorable reimbursements for naloxone products is expected to support the adoption of these products. Currently, most types of insurance cover and reimburse for naloxone administered directly in a medical setting.

Furthermore, some states in the U.S. have started covering take-home naloxone. Hence, adoption of take-home naloxone is expected to increase in the near future. For instance, in New York State from January 2014, the state’s Medicaid program began to cover the intramuscular formulation of take?home naloxone.

North America naloxone market is expected to a hold dominant position over the forecast period due to the presence of novel naloxone products such as Narcan nasal spray and EVZIO (naloxone hydrochloride injection), which is still not present in any other region. Furthermore, initiatives taken by various companies and organizations to increase access of naloxone is expected to fuel the market growth. For instance, in February 2018, Loyola Medicine and the Cook County Department of Homeland Security and Emergency Management collaborated, where Loyola Medicine trained police officials to use Narcan in case of opioids overdose. In 2016, Adapt Pharma Limited partnered with Smith Medical Partners, LLC for distribution of free Narcan (Naloxone HCl) nasal spray in all high schools in the U.S.

Furthermore, Europe naloxone market is expected to show significant growth in the near future, owing to increasing approvals of novel naloxone products in the region. For instance, in July 2017, Indivior Inc., a subsidiary of Indivior Plc., received marketing authorization (MA) from French Regulatory Agency ANSM for its new Nalscue naloxone hydrochloride nasal spray indicated for emergency treatment of characterized or suspected opioid overdose in France.

In February 2017, Adapt Pharma Limited filed marketing application for its product Naloxone Hydrochloride (HCl) nasal spray in Europe. Hence, these products when launched in the European market it will drastically fuel market growth in the near future

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1–206–701–6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.